November 24, 2017 11:04 PM ET


Company Overview of IRX Therapeutics, Inc.

Company Overview

IRX Therapeutics, Inc. develops immune therapies to treat cancer and related diseases. The company develops IRX-2, a platform technology that broadly restores the immune system by overcoming cancer-induced immune suppression. Its therapies target and restore the immune system to improve a patient’s response to cancer vaccines and targeted therapeutics. The company was founded in 1994 and is based in New York, New York.

140 West 57th Street

Suite 3D

New York, NY 10019

United States

Founded in 1994





Key Executives for IRX Therapeutics, Inc.

Chief Executive Officer, President and Director
Age: 60
Founder and Director
Founder and Director
Age: 48
Chief Financial Officer
Chief Operating Officer
Compensation as of Fiscal Year 2017.

IRX Therapeutics, Inc. Key Developments

IRX Therapeutics, Inc. Appoints Luba Greenwood to Its Board of Director

IRX Therapeutics, Inc. announced the appointment of Luba Greenwood, Vice President of Global Business Development and Mergers & Acquisitions at F. Hoffmann-La Roche, Diagnostics, to its Board of Directors. Luba Greenwood brings to the company a wealth of pharmaceutical and biotechnology industry experience, expertise in building innovative technology companies and providing strategic counsel to global corporations. Her career has spanned leadership roles in venture investing, business development, mergers & acquisitions, law, consulting and operations. Luba recently served as Venture Partner at Colt Ventures, and led business development and strategy for Pronutria. Prior to that, Luba served as Senior Mergers & Acquisitions Counsel at Pfizer Inc.

IRX Therapeutics, Inc. Announces Preliminary Results from Phase 1b Clinical Trial of IRX-2

IRX Therapeutics, Inc. announced the preliminary results from a Phase 1b clinical trial of IRX-2, the company’s lead drug candidate, in early stage breast cancer (ESBC) demonstrating that IRX-2 is well-tolerated in this population and reporting early signals of activity. The Phase 1b study is enrolling patients with early stage (I-III) breast cancer indicated for standard-of-care surgical lumpectomy/mastectomy. Twenty-one days prior to surgery, all patients receive a single low dose of cyclophosphamide (300 mg/m2), followed by 10 days of subcutaneous periareolar injections of IRX-2 into the affected breast. Total enrollment is expected to reach 20 patients. In the study, most toxicities reported were Grade 1, except for one report of Grade 2 headache and one report of Grade 2 nausea. Increases in stromal tumor infiltrating lymphocytes (sTILs) were observed in 7/12 patients with a mean 52% relative increase (range: -25% to +66%) and 6% absolute increase (range: -5% to +23%, p=0.02 paired t-test). IRX-2 increased leukocyte recruitment as well as levels of cytotoxic markers and checkpoints. Increases in gene expression associated with tumor suppression (FOS, EGR1, EGR2, CXCL2 and CXCR4), chemotaxis (CXCL12, ITGAE, RPS6) and T-cell activation (CD59, TNFAIP3, CDKN1A) were reported as well as up-regulation of PD-L1 as measured by Nanostring and multispectral IHC.

IRX Therapeutics, Inc. Presents at 2017 BIO Investor Forum, Oct-17-2017 09:30 AM

IRX Therapeutics, Inc. Presents at 2017 BIO Investor Forum, Oct-17-2017 09:30 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Private Placement
December 30, 2016

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact IRX Therapeutics, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at